ThesisCorporativo Fragua, S.A.B. de C.V.: the story is balanced — Mexican prescription drug market growth rates, driven by healthcare coverage expansion and chronic disease prevalence
value - The stock trades at 0.4x price/sales and 5.0x EV/EBITDA, well below typical healthcare multiples…
Rising interest rates have moderate negative impact through higher working capital financing costs…
Watch on earnings: Mexican peso exchange rate (DEXMXUS) affecting import costs for pharmaceutical products sourced internationally, Mexican healthcare spending as percentage of GDP and government budget allocations, Prescription volume trends and generic drug penetration rates in Mexican market.
One Sentence Summary:
Corporativo Fragua, S.A.B. de C.V.: the story is balanced — mexican prescription drug market growth rates, driven by healthcare coverage expansion and chronic disease prevalence.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
